How Merck keeps prices for its blockbuster cancer drug sky high

Merck’s Keytruda generated $31.7 billion in worldwide sales in 2025, but the article highlights how the company is using patents, dosing practices and lobbying to keep prices elevated and delay generic competition. U.S. patient and insurer bills ranged from about $15,000 to more than $162,000 per treatment, while Merck’s list price is $12,031 per 200 mg dose. The story could pressure sentiment around Merck and broader drug-pricing scrutiny, but it is unlikely to create an immediate large price move.

Analysis

MRK’s core risk is not near-term revenue leakage; it is the gradual conversion of a pricing narrative into a valuation overhang. Keytruda is still protected by a long patent runway and a reformulation strategy that can extend exclusivity, so the cash-flow machine remains intact for several years. But when nearly half of company revenue is concentrated in one asset, any incremental scrutiny around list pricing, 340B capture, or dosing optics can compress the multiple even if unit volume stays strong.

The more important second-order effect is political and reimbursement compression rather than generic erosion. Medicare negotiation delay buys time, but it also concentrates the eventual policy reset into a single future event; that increases tail risk for a sharp de-rating when the negotiation window finally opens. Meanwhile, hospitals and insurers are the immediate beneficiaries of the current system’s opacity: the spread between acquisition cost and billed price is large enough that provider behavior may remain the stronger earnings variable than Merck’s own discounting.

The contrarian view is that this is more a reputational and distribution-channel issue than a fundamental earnings break. The market may already assume high Keytruda durability, but it may be underestimating how much of MRK’s current valuation implicitly depends on the rest of the portfolio catching up before Keytruda’s pricing power is challenged. If that pipeline re-rating stalls, the stock can underperform even without a single earnings miss.

Timing matters: the catalyst path is slow for months, then potentially abrupt over 12-24 months as policy focus, hospital margin scrutiny, and alternative formulations converge. Near term, this reads as a multiple-risk trade rather than a revenue-risk trade, with downside most likely expressed through relative underperformance versus large-cap pharma rather than absolute collapse.

Key Decisions for Investors

• Initiate a tactical short MRK / long XLV pair for 3-6 months: target a 5-8% relative downside if pricing scrutiny broadens into a broader pharma multiple reset; stop if policy headlines fade and MRK outperforms defensives.
• Buy MRK downside via 6-12 month put spreads rather than outright short stock: limited carry, better if the market reprices patent/policy overhang before 2028-2029 exclusivity questions become acute.
• Avoid adding to long MRK ahead of any Medicare pricing-rule headlines; wait for a 10%+ pullback or a cleaner entry after the next policy milestone, because the stock’s risk/reward is skewed by headline risk more than fundamentals.
• Long hospital-provider beneficiaries with pricing leverage versus MRK, but hedge policy risk: prefer selective exposure to outpatient/provider names only if reimbursement pressure is not already embedded; otherwise the safer trade is relative underweight MRK versus diversified pharma.
• Set a 12-18 month alert around Keytruda negotiation and reformulation milestones; if adoption of the injectable version accelerates faster than expected, treat it as a signal to cut MRK longs and re-underwrite terminal exclusivity assumptions.